Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa.
about
Nonhuman primate models for HIV/AIDS vaccine developmentInduction of intestinal immunity by mucosal vaccines as a means of controlling HIV infectionChallenges in mucosal HIV vaccine development: lessons from non-human primate modelsTherapeutic DNA vaccine induces broad T cell responses in the gut and sustained protection from viral rebound and AIDS in SIV-infected rhesus macaquesConsensus HIV-1 FSU-A integrase gene variants electroporated into mice induce polyfunctional antigen-specific CD4+ and CD8+ T cellsMucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design.Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection.HIV controller CD4+ T cells respond to minimal amounts of Gag antigen due to high TCR avidity.HIV vaccination: turning the spotlight on effector memory T cells as mucosal gatekeepers.Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice.Vaccine-induced myeloid cell population dampens protective immunity to SIVInduction of resident memory T cells enhances the efficacy of cancer vaccineT-cell correlates of vaccine efficacy after a heterologous simian immunodeficiency virus challenge.Mucosal imprinting of vaccine-induced CD8⁺ T cells is crucial to inhibit the growth of mucosal tumorsHumoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses.Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques.Memories that last forever: strategies for optimizing vaccine T-cell memory.Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization.New approaches to design HIV-1 T-cell vaccinesCurrent progress in the development of a prophylactic vaccine for HIV-1.Prior exposure to an attenuated Listeria vaccine does not reduce immunogenicity: pre-clinical assessment of the efficacy of a Listeria vaccine in the induction of immune responses against HIV.Immune mechanisms of HIV control.HIV infection and the gastrointestinal immune systemComparative analysis of SIV-specific cellular immune responses induced by different vaccine platforms in rhesus macaquesInduction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulationsCharacterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant.Retinoic acid as a vaccine adjuvant enhances CD8+ T cell response and mucosal protection from viral challenge.High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV controlHigh-avidity, high-IFNγ-producing CD8 T-cell responses following immune selection during HIV-1 infection.Non-equilibrium and differential function between intraepithelial and lamina propria virus-specific TCRalphabeta(+) CD8alphabeta(+) T cells in the small intestinal mucosa.A comparative analysis of HIV-specific mucosal/systemic T cell immunity and avidity following rDNA/rFPV and poxvirus-poxvirus prime boost immunisationsTLR agonists and/or IL-15 adjuvanted mucosal SIV vaccine reduced gut CD4⁺ memory T cell loss in SIVmac251-challenged rhesus macaques.Virus-specific T cell responses in macaques acutely infected with SHIV(sf162p3).Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization.Problems and emerging approaches in HIV/AIDS vaccine development.Clarification of how HIV-1 DNA and protein immunizations may be better used to obtain HIV-1-specific mucosal and systemic immunity.Differential immunogenicity of vaccinia and HIV-1 components of a human recombinant vaccine in mucosal and blood compartments.Public T cell receptors confer high-avidity CD4 responses to HIV controllersMucosal vaccines: novel strategies and applications for the control of pathogens and tumors at mucosal sites.HIV/AIDS vaccines: a need for new concepts?
P2860
Q26861148-890C349C-3862-4E13-942B-C65B966DC236Q27001897-074DA90B-5E79-4ABD-9C19-2D3CB7F458AEQ27022152-9B33F12F-0C53-4EEE-A750-E5D9DDA3B080Q28481573-D0FCE70E-3CF1-45AF-8C94-90D7DD269387Q28487823-C9AF506F-D5D6-4599-A05A-AFB2E19EB6F2Q30375160-300391CE-A865-49E7-8FC3-91F43E3ADFDDQ33265482-5E339976-D12C-4C27-9414-66B017476862Q33535905-1D8E48AC-62D1-4038-842C-914539D4AB72Q33565035-0B545014-E73F-4EF8-BCDD-4C388D7510DCQ33609436-2066575F-9042-42C1-9379-BD1D1C0051BCQ33685961-9E5DCF3C-F639-4214-9104-85390DD53940Q33761198-5E7303D3-1F80-4569-9DD9-5735778D1CD1Q33826671-323D2D55-D914-45C1-AE28-96E43910EF2EQ33862822-205FEEDE-C388-4A5C-A8D6-CF4DDBFE3C86Q33915690-E50BCDA7-C6C9-4549-99CB-6DC9FFEE713FQ34006329-88579885-AE4E-4514-AD07-C95B69F0E324Q34060493-E4B7EC9F-0234-4DF0-8342-3977AA9E8AA2Q34099837-3471687A-5CC6-4D82-8022-393EFCB589E9Q34274849-B9F13E0E-1683-4079-8B45-C90681B69675Q34502108-4B3383E6-DE64-48CE-BDD8-A688B0C2D592Q34552488-A5282F28-83C5-46C9-A159-38D1F7046E24Q34575451-FC388F20-3C7B-43CA-B78B-69B6BA585BAEQ34601874-73002812-12CC-4565-9444-27A9CEB09BC9Q34616275-A92FEA67-06FC-4DC3-9747-72EB2812EEF3Q34641666-1F45BCB3-199D-42E7-B5A5-868A17DDEB7FQ35066293-4AB0E318-F7B4-4617-BBC2-72FB300E252AQ35140438-A4258962-A0EC-4866-87AE-3F1F12BFA7AEQ35192655-A6A3894F-0034-4AFB-B9F8-59D93F51B518Q35214354-DE7A4E6D-2230-4195-AE28-B3993B9B409FQ35575565-DB6C1A3B-A549-48E0-BD6A-F509FF9F22ECQ35628697-F65D2E64-5A09-4457-8F3B-978EF41E43B4Q35672335-2D0A1CA3-B2BC-4358-8843-BC33CCB8A08CQ35963420-029C9954-3D1F-4659-A182-7030C843A403Q36663607-9383219C-1631-4C2B-A652-A5F43A68022BQ36758574-EF39EADE-B395-4E04-9503-516419A47845Q36780136-933138DA-AEFA-420F-ACE7-AD9C2BDF1C54Q36943319-3D901DA5-2648-453C-977B-5A1CE43E7414Q36951735-39EDA4B7-BC21-44DB-BC48-9B9F6E66E74BQ36978334-AEC7A3C2-12B3-488A-ABCD-3C5A2C6D389DQ37344236-C97F55A8-7AD9-4008-A261-2CDFFB8E7E19
P2860
Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Impact of vaccine-induced muco ...... ral dissemination from mucosa.
@ast
Impact of vaccine-induced muco ...... ral dissemination from mucosa.
@en
type
label
Impact of vaccine-induced muco ...... ral dissemination from mucosa.
@ast
Impact of vaccine-induced muco ...... ral dissemination from mucosa.
@en
prefLabel
Impact of vaccine-induced muco ...... ral dissemination from mucosa.
@ast
Impact of vaccine-induced muco ...... ral dissemination from mucosa.
@en
P2093
P2860
P1433
P1476
Impact of vaccine-induced muco ...... ral dissemination from mucosa.
@en
P2093
Brian Kelsall
Dennis Klinman
Genoveffa Franchini
Igor M Belyakov
Jay A Berzofsky
John D Clements
Michael Lemon
Phillip D Markham
Ranajit Pal
Vladimir A Kuznetsov
P2860
P304
P356
10.1182/BLOOD-2005-11-4374
P407
P577
2005-12-22T00:00:00Z